MA30895B1 - Nouveaux anticorps anti-cd38 pour le traitement du cancer - Google Patents
Nouveaux anticorps anti-cd38 pour le traitement du cancerInfo
- Publication number
- MA30895B1 MA30895B1 MA31881A MA31881A MA30895B1 MA 30895 B1 MA30895 B1 MA 30895B1 MA 31881 A MA31881 A MA 31881A MA 31881 A MA31881 A MA 31881A MA 30895 B1 MA30895 B1 MA 30895B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- cytotoxic
- conjugates
- fragments
- leukemia
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
L'INVENTION CONCERNE DES ANTICORPS, DES ANTICORPS HUMANISÉS, DES ANTICORPS RESURFACÉS, DES FRAGMENTS D'ANTICORPS, DES ANTICORPS DÉRIVATISÉS, ET DES CONJUGUÉS DE CEUX-CI ET D'AGENTS CYTOTOXIQUES, QUI SE LIENT DE MANIÈRE SPÉCIFIQUE AU CD38, SONT CAPABLES D'ÉLIMINER DES CELLULES DE CD38+ PAR APOPTOSE, CYTOTOXICITÉ À MÉDIATION CELLULAIRE DÉPENDANTE DE L'ANTICORPS (ADCC), ET/OU CYTOTOXICITÉ DÉPENDANTE DU COMPLÉMENT (CDC). LESDITS ANTICORPS ET FRAGMENTS DE CEUX-CI PEUVENT ÊTRE UTILISÉS DANS LE TRAITEMENT DE TUMEURS QUI EXPRIMENT LA PROTÉINE CD38, DE TYPE MYÉLOME MULTIPLE, LEUCÉMIE LYMPHOÏDE CHRONIQUE, LEUCÉMIE MYÉLOÏDE CHRONIQUE, LEUCÉMIE MYÉLOÏDE AIGUË, OU LEUCÉMIE LYMPHOÏDE AIGUË, OU DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET INFLAMMATOIRES DE TYPE LUPUS ÉRYTHÉMATEUX SYSTÉMIQUE, POLYARTHRITE RHUMATOÏDE, SCLÉROSE EN PLAQUES, TROUBLES ÉRYTHÉMATEUX, ET ASTHME. LESDITS ANTICORPS DÉRIVATISÉS PEUVENT ÊTRE UTILISÉS DANS LE DIAGNOSTIC ET L'IMAGERIE DE TUMEURS QUI EXPRIMENT DES NIVEAUX ÉLEVÉS DE CD38. L'INVENTION CONCERNE ÉGALEMENT DES CONJUGUÉS CYTOTOXIQUES QUI COMPRENNENT UN AGENT DE LIAISON AUX CELLULES ET UN AGENT CYTOTOXIQUE, DES COMPOSITIONS THÉRAPEUTIQUES QUI COMPRENNENT LEDIT CONJUGUÉ, DES MÉTHODES D'UTILISATION DES CONJUGUÉS DANS L'INHIBITION DE LA CROISSANCE CELLULAIRE ET LE TRAITEMENT DE MALADIES, ET UN KIT QUI COMPREND LEDIT CONJUGUÉ CYTOTOXIQUE. EN PARTICULIER, L'AGENT DE LIAISON AUX CELLULES EST UN ANTICORPS MONOCLONAL, ET DES FRAGMENTS DE LIAISON AUX ÉPITOTES DE CELUI-CI, QUI RECONNAÎSSENT LA PROTÉINE CD38 ET QUI SE LIENT À CELLE-CI.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06291628A EP1914242A1 (fr) | 2006-10-19 | 2006-10-19 | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30895B1 true MA30895B1 (fr) | 2009-11-02 |
Family
ID=37831721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31881A MA30895B1 (fr) | 2006-10-19 | 2009-05-14 | Nouveaux anticorps anti-cd38 pour le traitement du cancer |
Country Status (43)
Families Citing this family (317)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
WO2006122355A1 (fr) * | 2005-05-16 | 2006-11-23 | Qrsciences Pty Ltd | Systeme et procede pour ameliorer l'analyse de substances chimiques par rqn |
CA2621982C (fr) | 2005-09-07 | 2017-11-28 | Jennerex Biotherapeutics Ulc | Traitement systemique de cancers metastasiques et/ou systemiquement dissemines a l'aide de poxvirus exprimant le gm-csf |
EP1945671A2 (fr) | 2005-10-12 | 2008-07-23 | MorphoSys AG | Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain |
EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
US7259237B1 (en) | 2006-12-29 | 2007-08-21 | Miller Kent D | Pan-antiviral peptides |
ES2435779T3 (es) | 2007-07-19 | 2013-12-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico |
PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
EP2191843A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide |
EP2191842A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine |
EP2191841A1 (fr) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine |
EP2191840A1 (fr) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
WO2011032180A1 (fr) | 2009-09-14 | 2011-03-17 | Jennerex, Inc. | Polythérapie anticancéreuse à virus de la vaccine oncolytique |
UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
HUE027713T2 (en) * | 2009-12-23 | 2016-10-28 | Hoffmann La Roche | Anti-BV8 antibodies and their use |
US9220743B2 (en) * | 2010-01-22 | 2015-12-29 | Nuovo Biologics, Llc | Pan-antiviral peptides for protein kinase inhibition |
US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
EP2558475A1 (fr) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazépines utilisées pour traiter des maladies prolifératives |
JP6093696B2 (ja) | 2010-06-09 | 2017-03-08 | ゲンマブ エー/エス | ヒトcd38に対する抗体 |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
ES2617446T3 (es) | 2010-09-27 | 2017-06-19 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
AU2012204467B2 (en) * | 2011-01-04 | 2016-08-18 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
KR102272828B1 (ko) | 2011-03-29 | 2021-07-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
RU2610336C2 (ru) | 2011-04-21 | 2017-02-09 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение |
EP3508500A1 (fr) * | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anticorps anti-cd40 et procédés d'utilisation |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
EP2710042A2 (fr) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation |
KR101860174B1 (ko) | 2011-09-20 | 2018-05-21 | 메디뮨 리미티드 | 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀 |
US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
CN110183470A (zh) | 2011-10-14 | 2019-08-30 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
US9399073B2 (en) | 2011-10-14 | 2016-07-26 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines |
BR112014009055B1 (pt) | 2011-10-14 | 2021-12-14 | Seattle Genetics, Inc. | Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa |
SG11201401518TA (en) | 2011-10-28 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
WO2013075740A1 (fr) * | 2011-11-23 | 2013-05-30 | Sanofi | Procédé de purification d'anticorps |
EP2812702B1 (fr) * | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnostic et prise en charge des cancers exprimant le CD30 |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
JP2015523380A (ja) | 2012-07-09 | 2015-08-13 | ジェネンテック, インコーポレイテッド | 抗cd79b抗体を含む免疫複合体 |
BR112015002193A2 (pt) | 2012-08-02 | 2017-07-04 | Genentech Inc | anticorpos anti-etbr e imunoconjugados |
PT2900232T (pt) | 2012-09-25 | 2018-02-09 | Morphosys Ag | Combinações e suas utilizações |
WO2014055415A1 (fr) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Traitements antinéoplasiques |
AU2013326881B2 (en) | 2012-10-04 | 2018-08-02 | Immunogen, Inc. | Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates |
EP2906250B1 (fr) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
PL2906253T3 (pl) | 2012-10-12 | 2019-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-psma |
MX364329B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
CA2885315C (fr) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines et leurs conjugues |
ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
KR101819404B1 (ko) | 2012-10-12 | 2018-02-28 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
CN105102068B (zh) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗体结合物 |
WO2014057072A1 (fr) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthèse et intermédiaires de dérivés de pyrrolobenzodiazépine pour conjugaison |
AU2013328628B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
WO2014068114A1 (fr) | 2012-11-05 | 2014-05-08 | Morphosys Ag | Anticorps radiomarqué et ses utilisations |
TWI609887B (zh) | 2012-11-05 | 2018-01-01 | 皮爾法伯製藥公司 | 新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途 |
UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
IL241407B (en) * | 2013-03-13 | 2022-06-01 | Univ California | Preparations containing antibodies against cd-38 and carfilzomib |
KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
BR112015023070B1 (pt) | 2013-03-13 | 2022-06-07 | Genentech, Inc. | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
JP6436965B2 (ja) | 2013-03-14 | 2018-12-12 | ジェネンテック, インコーポレイテッド | 抗b7−h4抗体及びイムノコンジュゲート |
PT2992013T (pt) | 2013-04-29 | 2020-03-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
HUE038741T2 (hu) * | 2013-05-06 | 2018-11-28 | Sanofi Sa | Folyamatos többlépéses eljárás antitestek tisztítására |
BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
CN105518027A (zh) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | 使用抗lgr5抗体的方法 |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052535A1 (fr) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Conjugués anticorps-pyrrolobenzodiazépine |
CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
JP2016536314A (ja) * | 2013-10-31 | 2016-11-24 | サノフイ | ヒトのがんを治療するための特異的抗cd38抗体 |
SG11201603244VA (en) | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
PE20160712A1 (es) | 2013-12-13 | 2016-07-26 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33 |
KR20160092024A (ko) | 2013-12-16 | 2016-08-03 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
CA2934617A1 (fr) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Conjugues de liant (conjugue anticorps-medicament) comprenant des inhibiteurs de la proteine kinesine du fuseau |
JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ, エルエルシー | 細胞外標的化薬物共役体 |
JP6673838B2 (ja) | 2014-02-14 | 2020-04-01 | セレクティスCellectis | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
BR112016022385A2 (pt) * | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
CN106414499A (zh) | 2014-05-22 | 2017-02-15 | 基因泰克公司 | 抗gpc3抗体和免疫偶联物 |
WO2015195555A1 (fr) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk |
US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
EP3154581B1 (fr) | 2014-06-16 | 2019-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocage de cd38 à l'aide de f(ab')2 anti-cd38 pour protéger les cellules nk |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
CA2959141A1 (fr) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Recepteurs d'antigenes chimeres conditionnellement actifs pour cellules t modifiees |
WO2016040294A2 (fr) * | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Polythérapies avec des anticorps anti-cd38 |
PT3191135T (pt) | 2014-09-12 | 2020-11-12 | Genentech Inc | Anticorpos anti-her2 e imunoconjugados |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
EP3191518B1 (fr) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anticorps anti-b7-h4 et immunoconjugués |
KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
CN113929782B (zh) * | 2014-09-16 | 2024-06-21 | 依奈特制药公司 | 对淋巴细胞中抑制途径的中和 |
JP6730261B2 (ja) | 2014-09-17 | 2020-07-29 | ジェネンテック, インコーポレイテッド | 抗her2抗体を含む免疫複合体 |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
CA2965414C (fr) | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Variantes de l'interferon .alpha.2.beta. |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
SG11201703599VA (en) | 2014-11-19 | 2017-06-29 | Immunogen Inc | Process for preparing cell-binding agent-cytotoxic agent conjugates |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
NZ732753A (en) * | 2014-12-04 | 2024-08-30 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MY189692A (en) | 2015-05-07 | 2022-02-26 | Memorial Sloan Kettering Cancer Center | Anti-ox40 antibodies and methods of use thereof |
HUE054271T2 (hu) | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
US9644032B2 (en) | 2015-05-29 | 2017-05-09 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
AU2016271124C1 (en) | 2015-05-30 | 2020-05-14 | Molecular Templates, Inc. | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
ES2890783T3 (es) | 2015-06-22 | 2022-01-24 | Janssen Biotech Inc | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina |
JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体(adc)および抗体プロドラッグ複合体(apdc) |
FI3313441T3 (fi) | 2015-06-24 | 2024-03-28 | Janssen Biotech Inc | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
CA2998611A1 (fr) * | 2015-09-14 | 2017-03-23 | Leukemia Therapeutics, LLC | Identification de nouveaux agents diagnostiques et therapeutiques par modulation de rhoh |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
WO2017060322A2 (fr) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Conjugué anticorps-médicament (adc) inhibiteur de ptefb |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
CN108472369A (zh) | 2015-11-03 | 2018-08-31 | 詹森生物科技公司 | 抗cd38抗体的皮下制剂及其用途 |
CN105837688B (zh) * | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞 |
IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
WO2017120501A1 (fr) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Procédés de traitement du cancer par interféron |
CN113817060B (zh) * | 2016-01-09 | 2024-03-08 | 嘉立医疗科技(广州)有限公司 | 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
EP3411077A1 (fr) | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
CA3016098A1 (fr) | 2016-03-04 | 2017-09-08 | Morphosys Ag | Evaluation clinique de reponse de proteine m dans le myelome multiple |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
WO2017165440A1 (fr) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Procédés de réduction de la toxicité d'un médicament chimiothérapeutique |
US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
KR20200087875A (ko) | 2016-04-15 | 2020-07-21 | 바이오아트라, 엘엘씨 | 항 Axl항체 및 이의 면역접합체와 이것들의 용도 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017196847A1 (fr) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux |
US11254742B2 (en) | 2016-05-13 | 2022-02-22 | Bioatla, Inc. | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
WO2017214182A1 (fr) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse |
CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
US20190233533A1 (en) * | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
EP3475304B1 (fr) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine |
EP3484923A1 (fr) * | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
CN117717604A (zh) | 2016-07-19 | 2024-03-19 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
EP3487506A1 (fr) | 2016-07-20 | 2019-05-29 | Hybrigenics SA | Combinaisons d'inéclacitol avec un agent anti-cd38 et leurs utilisations pour le traitement du cancer |
CA3031559A1 (fr) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps monoclonaux ciblant le glypican-2 (gpc2) et leur utilisation |
WO2018031662A1 (fr) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci |
JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research | T細胞癌を標的とする為の方法及び組成物 |
EP3506942B1 (fr) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers |
CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
EP3510048A1 (fr) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Procédés de traitement du cancer exprimant pd-l1 |
WO2018048815A1 (fr) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
WO2018089628A1 (fr) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
CA3036983A1 (fr) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anticorps anti-gp73 et immunoconjugues |
US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
CA3047491A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Promedicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique |
JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
EP3558387B1 (fr) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Conjugués anticorps-principe actif (adc) spécifiques renfermant des inhibiteurs de ksp |
CN109963570A (zh) | 2017-01-21 | 2019-07-02 | 宁波知明生物科技有限公司 | 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PL3544636T3 (pl) | 2017-02-08 | 2021-12-06 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało |
RS63502B1 (sr) | 2017-04-18 | 2022-09-30 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
CA3057748A1 (fr) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Polytherapie avec un conjugue anticorps anti-axl-medicament |
WO2018213064A1 (fr) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps monoclonal humain ciblant tnfer2 en immunothérapie anticancéreuse |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
WO2018234370A1 (fr) | 2017-06-20 | 2018-12-27 | Institut Curie | Cellules immunitaires défectueuses vis-à-vis de suv39h1 |
US11191845B2 (en) | 2017-06-20 | 2021-12-07 | Sorrento Therapeutics, Inc. | CD38 antibody drug conjugate |
CA3066953A1 (fr) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Anticorps monoclonaux humains specifiques de cd33 et leurs procedes d'utilisation |
WO2019005208A1 (fr) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse |
EP3434692A1 (fr) * | 2017-07-24 | 2019-01-30 | Encefa | Composes se liant specifiquement a cd38 pour leur utilisation dans le traitement de maladies neurodegeneratives |
BR112020002636A2 (pt) * | 2017-08-10 | 2020-07-28 | Grifols Diagnostic Solutions Inc. | composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano |
AU2018316521A1 (en) * | 2017-08-16 | 2020-02-13 | Black Belt Therapeutics Limited | CD38 modulating antibody |
SG11202000484TA (en) * | 2017-08-16 | 2020-02-27 | Black Belt Therapeutics Ltd | Cd38 antibody |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
NZ761175A (en) | 2017-08-18 | 2024-07-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2019055689A1 (fr) | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Anticorps à chaîne lourde se liant à des exoenzymes |
JP2020533380A (ja) * | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 癌の組合せ治療 |
KR20200061376A (ko) | 2017-09-29 | 2020-06-02 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 콘쥬게이트 |
WO2019070726A1 (fr) * | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Molécules d'anticorps se liant à cd73 et leurs utilisations |
MX2020004129A (es) * | 2017-10-10 | 2020-08-20 | Sanofi Sa | Anticuerpos anti-cd38 y metodos de uso. |
MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
WO2019089848A1 (fr) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Procédés associés à une charge tumorale pour évaluer une réponse à une thérapie cellulaire |
CN111542596A (zh) | 2017-11-01 | 2020-08-14 | 朱诺治疗学股份有限公司 | 产生工程化细胞的治疗性组合物的方法 |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
MX2020004239A (es) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Proceso para producir una composicion de celulas t. |
TW201932482A (zh) | 2017-11-01 | 2019-08-16 | 美商奇諾治療有限公司 | 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸 |
WO2019089969A2 (fr) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
EP3706785A4 (fr) * | 2017-11-10 | 2021-08-04 | Actinium Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie hématologique |
MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたt細胞の組成物を製造するための方法 |
SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
WO2019149743A1 (fr) | 2018-01-30 | 2019-08-08 | Cellectis | Association comprenant des cellules immunitaires allogéniques déficientes pour un antigène présent sur les cellules t et sur des cellules pathologiques, et anticorps thérapeutique contre ledit antigène |
CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
EP3762031A4 (fr) * | 2018-03-08 | 2021-12-22 | Phanes Therapeutics, Inc. | Anticorps anti-claudine 18.2 et leurs utilisations |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US12048745B2 (en) | 2018-05-01 | 2024-07-30 | Augusta University Research Institute, Inc. | Methods for detecting and reversing immune therapy resistance |
BR112020023187A2 (pt) | 2018-05-16 | 2021-04-20 | Janssen Biotech, Inc. | métodos para tratamento de cânceres e de aumento da eficácia de agentes terapêuticos de redirecionamento de células t |
CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd38抗体及其用途 |
TW202019962A (zh) | 2018-07-10 | 2020-06-01 | 法商賽諾菲公司 | 標靶CD38及TGF-β的組合療法 |
US11939377B2 (en) | 2018-07-12 | 2024-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
US20240254252A1 (en) | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
TW202019518A (zh) | 2018-07-13 | 2020-06-01 | 丹麥商珍美寶股份有限公司 | Cd38抗體之變體及其用途 |
EP3833684A1 (fr) | 2018-08-08 | 2021-06-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anticorps monoclonaux à haute affinité ciblant le glypicane-2 et leurs utilisations |
SG11202101130VA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids |
AU2019338999A1 (en) * | 2018-09-11 | 2021-03-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
EP3867275A2 (fr) | 2018-10-17 | 2021-08-25 | Janssen Biotech, Inc. | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 |
US20210388106A1 (en) | 2018-10-26 | 2021-12-16 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
SG11202103873VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
MA54248A (fr) | 2018-11-13 | 2021-09-22 | Janssen Biotech Inc | Régulation de métaux traces pendant la production d'anticorps anti-cd38 |
WO2020120730A1 (fr) * | 2018-12-14 | 2020-06-18 | Morphosys Ag | Formulations d'anticorps |
CN113490510A (zh) | 2019-01-08 | 2021-10-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体 |
AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
CN113474362B (zh) * | 2019-01-28 | 2023-04-18 | 普众发现医药科技(上海)有限公司 | 对cd44特异性的抗体 |
MA54860A (fr) | 2019-01-28 | 2022-05-04 | Sanofi Sa | Méthodes de traitement du myélome multiple |
CA3130695A1 (fr) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosage pour traitement avec des anticorps anti-tigit et anti-cd20 ou anti-cd38 |
KR20220002891A (ko) | 2019-03-15 | 2022-01-07 | 모르포시스 아게 | 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물 |
TW202104269A (zh) * | 2019-04-23 | 2021-02-01 | 法商賽諾菲公司 | 抗cd38抗體和調配物 |
SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
BR112021022503A2 (pt) | 2019-05-14 | 2021-12-28 | Sanofi Sa | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
WO2020261219A1 (fr) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Utilisation de lymphocytes t récepteurs d'antigènes chimériques et d'inhibiteurs de cellules nk pour le traitement du cancer |
MX2021015433A (es) | 2019-07-02 | 2022-06-08 | Hutchinson Fred Cancer Res | Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas. |
AU2020318781A1 (en) | 2019-07-23 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immune cells defective for SUV39H1 |
CA3155246A1 (fr) * | 2019-10-21 | 2021-04-29 | Sandro MATOSEVIC | Cellules tueuses naturelles modifiees et leurs methodes d'utilisation dans des techniques d'immunotherapie et d'inhibition de l'autophagie |
JP2022552875A (ja) | 2019-10-22 | 2022-12-20 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ |
WO2021092171A1 (fr) | 2019-11-06 | 2021-05-14 | Genentech, Inc. | Méthodes diagnostiques et thérapeutiques pour le traitement de cancers hématologiques |
GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
US20210188996A1 (en) | 2019-12-05 | 2021-06-24 | Sanofi-Aventis U.S. Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
EP4069740A1 (fr) * | 2019-12-06 | 2022-10-12 | Sanofi-Aventis U.S. LLC | Utilisation d'isatuximab pour le traitement d'un myélome multiple réfractaire et/ou récidivant |
CA3161573A1 (fr) | 2019-12-12 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Conjugues anticorps-medicament specifiques a cd276 et leurs utilisations |
JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー, インコーポレイテッド | Cd38に結合する重鎖抗体 |
WO2021144457A1 (fr) | 2020-01-16 | 2021-07-22 | Genmab A/S | Formulations d'anticorps anti-cd38 et leurs utilisations |
WO2021207689A2 (fr) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b |
KR20230005268A (ko) * | 2020-04-24 | 2023-01-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-cd19 항체 및 이의 용도 |
CN115803824A (zh) | 2020-05-13 | 2023-03-14 | 朱诺治疗学股份有限公司 | 鉴定与临床反应相关的特征的方法及其用途 |
CN116234558A (zh) | 2020-06-26 | 2023-06-06 | 朱诺治疗学有限公司 | 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法 |
WO2021260657A1 (fr) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 |
CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆(苏州)医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
KR20230074713A (ko) | 2020-07-30 | 2023-05-31 | 엥스띠뛰 퀴리 | Socs1에 결함이 있는 면역 세포 |
CN114075285B (zh) * | 2020-08-20 | 2023-05-30 | 瑞阳(苏州)生物科技有限公司 | 抗人cd38人源化单克隆抗体及其应用 |
EP4211244A1 (fr) | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Compositions et procédés pour la modification de cd38 |
US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
CN112300281B (zh) * | 2020-10-29 | 2021-06-11 | 杭州爱唯生命科技有限公司 | 含有nk细胞的药物组合物及其治疗癌症的用途 |
US20220135696A1 (en) | 2020-11-03 | 2022-05-05 | Sanofi-Aventis U.S. Llc | Use of isatuximab for the treatment of multiple myeloma |
WO2022098787A1 (fr) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés |
EP4251282A1 (fr) | 2020-11-27 | 2023-10-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédés de diagnostic et de surveillance de la nécrolyse épidermique toxique |
WO2022117572A2 (fr) | 2020-12-02 | 2022-06-09 | Oncurious Nv | Agoniste de ltbr utilisé pour la polythérapie contre le cancer |
US20220202859A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
WO2022152823A1 (fr) | 2021-01-14 | 2022-07-21 | Morphosys Ag | Anticorps anti-cd38 et leurs utilisations |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
WO2022232612A1 (fr) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nanocorps spécifiques du virus de lassa et leurs méthodes d'utilisation |
WO2022234009A2 (fr) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Méthodes de stimulation et de transduction de lymphocytes t |
US20240269282A1 (en) | 2021-05-10 | 2024-08-15 | Institut Curie | Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases |
TW202309077A (zh) | 2021-05-12 | 2023-03-01 | 瑞士商Crispr治療公司 | 用於治療實性瘤的靶向cd70的基因工程化免疫細胞 |
WO2022238962A1 (fr) | 2021-05-12 | 2022-11-17 | Crispr Therapeutics Ag | Cellules immunitaires génétiquement modifiées ciblant cd70 pour une utilisation dans le traitement de malignités hématopoïétiques |
CN113244175B (zh) * | 2021-05-22 | 2022-11-04 | 苏州大学 | 一种免疫囊泡美登素偶联物及其制备方法与应用 |
WO2022248602A1 (fr) | 2021-05-25 | 2022-12-01 | Institut Curie | Cellules myéloïdes surexprimant bcl2 |
CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
WO2022271987A1 (fr) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anticorps anti-cd38 et leurs épitopes |
TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
MX2024001211A (es) | 2021-07-28 | 2024-02-12 | Genentech Inc | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre. |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
CN113896802A (zh) * | 2021-10-09 | 2022-01-07 | 宜明昂科生物医药技术(上海)有限公司 | 靶向cd47和cd38的重组融合蛋白及其制备和用途 |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
WO2023081705A1 (fr) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Méthodes de traitement de cancers et d'amélioration de l'efficacité d'anticorps bispécifiques bcmaxcd3 |
CA3237175A1 (fr) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Reduction de corticosteroide dans un traitement avec des anticorps anti-cd38 |
CN113912727B (zh) * | 2021-11-16 | 2023-05-02 | 福州迈新生物技术开发有限公司 | 抗cd38蛋白单克隆抗体、细胞系及其制备方法和应用 |
WO2023126458A1 (fr) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Cellules immunitaires avec suv39h1 inactivé et tcr modifié |
CN114457017B (zh) * | 2022-01-19 | 2023-10-17 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用 |
WO2023147515A1 (fr) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Procédés de fabrication de compositions cellulaires |
WO2023144303A1 (fr) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 en tant que biomarqueur et biocible dans des lymphomes t |
WO2023159182A1 (fr) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Molécules d'anticorps anti-ligand de mort cellulaire programmée 1 (pd-l1), polynucléotides de codage et méthodes d'utilisation |
AU2023231217A1 (en) | 2022-03-07 | 2024-10-17 | Marielle CHIRON BLONDEL | Use of isatuximab in combination with other agents for the treatment of multiple myeloma |
WO2023187024A1 (fr) | 2022-03-31 | 2023-10-05 | Institut Curie | Protéine rela modifiée pour induire l'expression d'interféron et cellules immunitaires modifiées ayant une expression d'interféron améliorée |
WO2023215737A1 (fr) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anticorps anti-ly6e, immunoconjugués et leurs utilisations |
WO2023213969A1 (fr) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés |
WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
WO2023230548A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédé de prédiction d'une réponse à une thérapie par lymphocyte t |
WO2023230581A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédés de fabrication de thérapies par lymphocytes t |
WO2023240135A2 (fr) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Chélateurs et conjugués bifonctionnels |
WO2024040151A1 (fr) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Polythérapies de protéine de fusion sirp alpha et d'anticorps anti-cd38 |
WO2024054944A1 (fr) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combinaison de thérapie cellulaire t et de dosage continu ou intermittent d'inhibiteurs de dgk |
TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Gprc5d tcb及cd38抗體之組合療法 |
WO2024094660A1 (fr) | 2022-10-31 | 2024-05-10 | Genmab A/S | Anticorps cd38 et leurs utilisations |
WO2024095173A1 (fr) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Méthodes de traitement de cancers |
WO2024100604A1 (fr) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Procédés de fabrication de cellules immunitaires modifiées |
WO2024124132A1 (fr) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Procédés d'apprentissage automatique pour prédire un phénotype cellulaire au moyen d'une imagerie holographique |
WO2024161021A1 (fr) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Procédés de fabrication non virale de cellules immunitaires modifiées |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
US2429004A (en) | 1947-02-20 | 1947-10-14 | Wachsman Michael | Fabric contacting circuit closer for knitting machines |
FR1516743A (fr) | 1966-04-01 | 1968-02-05 | Rhone Poulenc Sa | Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (fr) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production d'anticorps utilisant des librairies de genes |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1992022653A1 (fr) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Procede de production d'anticorps humanises |
WO1992022324A1 (fr) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Fragments d'anticorps produits par des microbes et leurs conjugues |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0563475B1 (fr) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Conjugués d'agents ciblés et de dérivés du CC-1065 |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
JPH06511156A (ja) * | 1992-07-16 | 1994-12-15 | イコス コーポレイション | 炎症性疾患状態に関連する症状の緩和 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
WO1998046645A2 (fr) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
AU757510C (en) | 1998-08-27 | 2003-09-11 | Medimmune Limited | Pyrrolobenzodiazepines |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
JP2003534022A (ja) * | 2000-05-26 | 2003-11-18 | スミスクライン・ビーチャム・コーポレイション | Rankリガンド介在障害の治療に有用な抗−rankリガンドモノクローナル抗体 |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EA013224B1 (ru) | 2000-10-06 | 2010-04-30 | Киова Хакко Кирин Ко., Лтд. | Клетки, продуцирующие композиции антител |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
EP1498490A4 (fr) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | Procede de production de composition anticorps |
EP1498491A4 (fr) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
EP3502133A1 (fr) | 2002-09-27 | 2019-06-26 | Xencor, Inc. | Variantes fc optimisées et leurs procédés de génération |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
AU2003295411A1 (en) * | 2002-11-07 | 2004-06-03 | Celltech R & D | Human monoclonal antibodies to heparanase |
CA2504818C (fr) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anticorps anti-cd33 et methode de traitement de la leucemie myeloide aigue a l'aide dudit anticorps |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
WO2005014649A2 (fr) * | 2003-08-08 | 2005-02-17 | Pharmacia Corporation | Methode de preparation de molecules ayant une activite d'anticorps |
US20050208627A1 (en) * | 2003-09-18 | 2005-09-22 | Bowdish Katherine S | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
AU2004280066A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Genomically modified cell |
ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
WO2005056766A2 (fr) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 |
ES2541489T3 (es) * | 2004-02-06 | 2015-07-21 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
EP1723152B1 (fr) | 2004-03-09 | 2015-02-11 | Spirogen Sàrl | Pyrrolobenzodiazépines |
EP2360186B1 (fr) * | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anticorps dirigés contre la sélectine P |
WO2005103081A2 (fr) * | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
JP2008504029A (ja) * | 2004-06-21 | 2008-02-14 | ワシントン・ユニバーシティ | 西ナイルウイルスに対する抗体ならびにその治療的および予防的使用 |
EP2471813B1 (fr) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Variantes optimisées de Fc |
US7732131B2 (en) * | 2004-08-03 | 2010-06-08 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
WO2006047350A2 (fr) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | Variants d'immunoglobuline igg a fonction effectrice optimisee |
WO2006066171A1 (fr) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Anticorps amyloide ???? utilises afin d'ameliorer la cognition |
AU2006214121B9 (en) * | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
CN107033243B (zh) * | 2005-03-23 | 2020-12-15 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
US20090123950A1 (en) * | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
DE102005030112A1 (de) | 2005-06-28 | 2007-01-18 | Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH | Lötzusatzwerkstoff |
CA2624189A1 (fr) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees |
ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
EP1864682A1 (fr) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Dérivés de la Leptomycine |
EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
NZ590330A (en) | 2008-07-21 | 2012-08-31 | Immunomedics Inc | Structural variants of anti-cd20 antibodies for improved therapeutic characteristics |
ES2617446T3 (es) * | 2010-09-27 | 2017-06-19 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
SG11201401518TA (en) * | 2011-10-28 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
WO2013125861A1 (fr) | 2012-02-20 | 2013-08-29 | 주식회사 노리코리아 | Procédé et système de fourniture d'un service éducatif sur la base d'une unité de connaissances, et support d'enregistrement lisible par ordinateur |
US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
WO2016040294A2 (fr) * | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Polythérapies avec des anticorps anti-cd38 |
NZ732753A (en) * | 2014-12-04 | 2024-08-30 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
WO2016111677A1 (fr) * | 2015-01-06 | 2016-07-14 | Hewlett-Packard Development Company, L.P. | Adaptateur de concaténation de connecteurs |
KR102602754B1 (ko) * | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
ES2890783T3 (es) * | 2015-06-22 | 2022-01-24 | Janssen Biotech Inc | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina |
US20170044265A1 (en) * | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
CN108472369A (zh) * | 2015-11-03 | 2018-08-31 | 詹森生物科技公司 | 抗cd38抗体的皮下制剂及其用途 |
US10781261B2 (en) * | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
MX2020004129A (es) * | 2017-10-10 | 2020-08-20 | Sanofi Sa | Anticuerpos anti-cd38 y metodos de uso. |
US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2006
- 2006-10-19 EP EP06291628A patent/EP1914242A1/fr not_active Ceased
-
2007
- 2007-10-16 KR KR1020177033125A patent/KR101852317B1/ko active IP Right Grant
- 2007-10-16 CA CA2989609A patent/CA2989609A1/fr not_active Abandoned
- 2007-10-16 KR KR1020147020922A patent/KR101534452B1/ko active IP Right Grant
- 2007-10-16 SG SG2011064136A patent/SG174777A1/en unknown
- 2007-10-16 PT PT07859236T patent/PT2076540T/pt unknown
- 2007-10-16 NO NO20091712A patent/NO345911B1/no active Protection Beyond IP Right Term
- 2007-10-16 KR KR1020157029059A patent/KR101800328B1/ko active IP Right Grant
- 2007-10-16 RS RS20190583A patent/RS58716B1/sr unknown
- 2007-10-16 KR KR1020097007903A patent/KR20090078330A/ko not_active Application Discontinuation
- 2007-10-16 MY MYPI20091535A patent/MY159374A/en unknown
- 2007-10-16 MX MX2009004050A patent/MX2009004050A/es active IP Right Grant
- 2007-10-16 SG SG10201501733QA patent/SG10201501733QA/en unknown
- 2007-10-16 EP EP19150990.0A patent/EP3498735A1/fr not_active Withdrawn
- 2007-10-16 HU HUE07859236A patent/HUE043351T2/hu unknown
- 2007-10-16 PL PL07859236T patent/PL2076540T3/pl unknown
- 2007-10-16 AU AU2007311511A patent/AU2007311511C1/en active Active
- 2007-10-16 ES ES07859236T patent/ES2726754T3/es active Active
- 2007-10-16 ZA ZA200901395A patent/ZA200901395B/xx unknown
- 2007-10-16 NO NO20211026A patent/NO20211026A1/no unknown
- 2007-10-16 WO PCT/IB2007/004172 patent/WO2008047242A2/fr active Application Filing
- 2007-10-16 LT LTEP07859236.7T patent/LT2076540T/lt unknown
- 2007-10-16 EP EP20207633.7A patent/EP3909980A1/fr active Pending
- 2007-10-16 BR BRPI0718130-2A patent/BRPI0718130B1/pt active IP Right Grant
- 2007-10-16 SG SG10202012950TA patent/SG10202012950TA/en unknown
- 2007-10-16 JP JP2009532912A patent/JP5607364B2/ja active Active
- 2007-10-16 EA EA200970393A patent/EA025215B1/ru active Protection Beyond IP Right Term
- 2007-10-16 CN CN200780038983.6A patent/CN101616933B/zh active Active
- 2007-10-16 EP EP07859236.7A patent/EP2076540B1/fr active Active
- 2007-10-16 DK DK07859236.7T patent/DK2076540T3/da active
- 2007-10-16 US US12/441,466 patent/US8153765B2/en active Active
- 2007-10-16 SG SG2011048956A patent/SG173345A1/en unknown
- 2007-10-16 SI SI200732106T patent/SI2076540T1/sl unknown
- 2007-10-16 ME MEP-106/09A patent/MEP10609A/xx unknown
- 2007-10-16 NZ NZ575188A patent/NZ575188A/en not_active Application Discontinuation
- 2007-10-16 UA UAA200904921A patent/UA114879C2/uk unknown
- 2007-10-16 KR KR1020157000867A patent/KR20150023010A/ko not_active Application Discontinuation
- 2007-10-16 CA CA2663209A patent/CA2663209C/fr not_active Expired - Fee Related
- 2007-10-17 PE PE2007001402A patent/PE20081171A1/es active IP Right Grant
- 2007-10-18 AR ARP070104617A patent/AR063488A1/es active IP Right Grant
- 2007-10-18 TW TW096139053A patent/TWI538917B/zh active
- 2007-10-18 TW TW103126457A patent/TWI609884B/zh active
- 2007-10-18 TW TW105100113A patent/TWI609885B/zh active
- 2007-10-18 CL CL200702995A patent/CL2007002995A1/es unknown
- 2007-10-18 TW TW106119286A patent/TW201734053A/zh unknown
- 2007-10-19 UY UY30655A patent/UY30655A1/es not_active Application Discontinuation
-
2009
- 2009-02-24 IL IL197217A patent/IL197217B/en active IP Right Grant
- 2009-02-24 TN TN2009000058A patent/TN2009000058A1/fr unknown
- 2009-03-20 CR CR10679A patent/CR10679A/es unknown
- 2009-04-02 SV SV2009003203A patent/SV2009003203A/es not_active Application Discontinuation
- 2009-04-13 GT GT200900079A patent/GT200900079A/es unknown
- 2009-04-17 CO CO09039181A patent/CO6190555A2/es active IP Right Grant
- 2009-05-14 MA MA31881A patent/MA30895B1/fr unknown
-
2010
- 2010-06-17 HK HK10106034.3A patent/HK1139956A1/xx unknown
-
2011
- 2011-03-23 US US13/069,705 patent/US20110262454A1/en not_active Abandoned
-
2012
- 2012-02-14 US US13/372,770 patent/US20120156218A1/en not_active Abandoned
- 2012-07-19 CL CL2012002012A patent/CL2012002012A1/es unknown
-
2014
- 2014-06-04 JP JP2014115665A patent/JP6121366B2/ja active Active
-
2017
- 2017-01-09 US US15/402,081 patent/US20170343550A1/en not_active Abandoned
- 2017-06-16 CL CL2017001580A patent/CL2017001580A1/es unknown
- 2017-07-31 DO DO2017000177A patent/DOP2017000177A/es unknown
-
2019
- 2019-04-18 HR HRP20190742TT patent/HRP20190742T1/hr unknown
- 2019-05-27 CY CY20191100563T patent/CY1122302T1/el unknown
-
2020
- 2020-02-07 US US16/784,577 patent/US20200408765A1/en not_active Abandoned
- 2020-11-25 NL NL301077C patent/NL301077I2/nl unknown
- 2020-11-25 HU HUS2000048C patent/HUS2000048I1/hu unknown
- 2020-11-26 CY CY2020039C patent/CY2020039I2/el unknown
- 2020-11-27 LT LTPA2020536C patent/LTPA2020536I1/lt unknown
-
2021
- 2021-10-13 NO NO2021044C patent/NO2021044I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30895B1 (fr) | Nouveaux anticorps anti-cd38 pour le traitement du cancer | |
JP7260621B2 (ja) | Bcma(cd269/tnfrsf17)結合タンパク質 | |
JP7022707B2 (ja) | Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc) | |
US10918735B2 (en) | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | |
JP2020048559A (ja) | 抗FcRH5抗体 | |
CA2881764C (fr) | Agents de liaison a kir3dl2 | |
TWI756633B (zh) | 具有改善的同質性的抗體-藥物綴合物、其藥物組合物、用途和製備方法 | |
KR20170138451A (ko) | 항-c-met 항체 및 항-c-met 항체-세포독성 약물 컨쥬게이트 및 이의 약학적 용도 | |
KR20160037130A (ko) | 신규한 항체 접합체 및 이의 용도 | |
KR20180018808A (ko) | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) 및 항체 전구약물 접합체 (apdc) | |
JP2017534256A (ja) | Anti−cll−1抗体及び免疫複合体 | |
MA30634B1 (fr) | Anticorps antagoniste pour le traitement du cancer | |
KR20150013318A (ko) | 항-Ly6E 항체 및 면역접합체 및 사용 방법 | |
KR20150030754A (ko) | 항-cd22 항체를 포함하는 면역접합체 | |
JP2020527332A (ja) | 抗−il1rap抗体および抗体薬物コンジュゲート | |
KR20210086683A (ko) | 동종이형 조혈 줄기 세포 이식 방법 | |
BR112020021061A2 (pt) | anticorpos, polinucleotídeo isolado, vetor, kit ou composição, célula hospedeira e método de produção de um anticorpo | |
JP2022553839A (ja) | 抗-cd45抗体及びそのコンジュゲート | |
JP5102612B2 (ja) | B細胞疾患の標的 | |
JP2022116185A (ja) | サイトカイン阻害剤と組み合わせて使用するための抗t細胞抗原結合分子 | |
KR20150032886A (ko) | 항-etbr 항체 및 면역접합체 | |
TW202406934A (zh) | 抗Ly6E抗體、免疫結合物及其用途 | |
Shivakumar et al. | Highlights From: 6th International Congress on Monoclonal Antibodies in Cancer; August 2006, Washington, DC | |
KR20230131204A (ko) | 암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체 |